Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
FULCthis companyFulcrum Therapeutics, Inc.	$3.73	-9.58×	2.05×	0×	-7.15×	-17.6%	0.0%	0.0%	0.0%	-21.5%	-23.8%	-8.4%	0.02×	2.6×	0×	27.4×	0.0%	2	10.2	3	B
CMPXCompass Therapeutics, Inc.	$0.80	-12.79×	4.3×	0×	-12.7×	-84.0%	0.0%	0.0%	0.0%	-33.8%	-35.3%	-5.8%	0.05×	0.32×	0×	15.02×	0.0%	3	-0.29	2	C+
LCTXLineage Cell Therapeutics, Inc.	$1.03	-5.96×	8.63×	26.4×	-5.09×	-251.4%	94.2%	-149.6%	-436.5%	-142.6%	-19.7%	-5.1%	0.05×	0.56×	0×	5.2×	0.0%	3	-3.44	1	C-
LXRXLexicon Pharmaceuticals, Inc.	$1.88	-8.21×	3.88×	8.38×	-10.76×	-701.5%	99.4%	-98.2%	-101.1%	-46.8%	-28.7%	-16.3%	0.58×	-0.67×	-5.87×	4.88×	0.0%	2	-6.05	1	D+
NGNENeurogene Inc.	$26.18	-4.86×	1.65×	0×	-3.92×	-83.6%	0.0%	0.0%	0.0%	-34.1%	-37.5%	-18.0%	0.04×	1.08×	-20,641.6×	16.56×	0.0%	1	6.39	2	C
NMRANeumora Therapeutics, Inc. Common Stock	$0.54	-1.23×	2.82×	0×	-0.47×	121.4%	0.0%	0.0%	0.0%	-228.1%	-151.8%	-70.6%	0×	0.78×	-74.92×	5.87×	0.0%	2	-18.15	2	C+
Peer median	—	-5.96×	3.88×	0×	-5.09×	-84.0%	0.0%	0.0%	0.0%	-46.8%	-35.3%	-16.3%	0.05×	0.56×	-5.87×	5.87×	0.0%	2	-3.44	2	—